recombinant factor XIII-A2: Clinical Trials

6 trials of recombinant factor XIII-A2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated. 2 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2
Phase 11Completed 1
Phase 21Terminated 1

Follow recombinant factor XIII-A2: new trials by email Literature Review of recombinant factor XIII-A2 trials Research Report on recombinant factor XIII-A2

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
recombinant factor XIII - Congenital Bleeding Disorder, Congenital FXIII Deficiency
CompletedNovo Nordisk A/S82016-03-162025-08-29
Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study
catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency
CompletedNovo Nordisk A/S302013-05-172019-07-09
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
catridecacog, placebo - Inflammation, Ulcerative Colitis
Phase 2TerminatedNovo Nordisk A/S202012-10-012014-10-02
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency
Phase 3CompletedNovo Nordisk A/S62011-01-012016-06-24
Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
catridecacog, recombinant factor XIII - Congenital Bleeding Disorder, Congenital FXIII Deficiency
Phase 1CompletedNovo Nordisk A/S512010-03-012016-09-21
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency
Phase 3CompletedNovo Nordisk A/S632009-09-212018-01-24

Conditions studied

Colitis, Ulcerative (1)  ·  Inflammation (1)

Sponsors

Novo Nordisk A/S (6)

Countries

United Kingdom (4)  ·  United States (3)  ·  Canada (2)  ·  Hungary (2)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  Austria (1)  ·  Bulgaria (1)  ·  Croatia (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)

Results publications

PMID 25263390, PMID 25643920, PMID 28581691, PMID 37883802

NIH funding

2008 (1), 2009 (1)